Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer

21 Feb 2017

Abstract excerpt

In recent years, sorafenib [1] and lenvatinib [2] have demonstrated efficacy in the first-line setting for advanced or metastatic differentiated thyroid cancer refractory to radioactive iodine (RAI). During the same time, the specific inhibition of BRAF in BRAF-mutated tumors showed important efficacy [3], including in papillary thyroid cancer (PTC) [4]. Furthermore, the ability of targeted therapies to induce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Medical Imaging Techniques and Applications
Share to S100 Proteins and Annexins
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29264486
DOI: 10.1210/js.2016-1114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid CancerPMID 29264486Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.Semantic proximity Read ↗

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?Semantic proximity Read ↗

Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E-Mutant papillary thyroid carcinoma.Semantic proximity Read ↗

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases.Semantic proximity Read ↗

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.Semantic proximity Read ↗

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.Semantic proximity Read ↗

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.Semantic proximity Read ↗

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.Semantic proximity Read ↗

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.Semantic proximity Read ↗

Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.Semantic proximity Read ↗

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.